Matthew Schabacker - 02 Mar 2026 Form 4 Insider Report for CONMED Corp (CNMD)

Role: VP GM Advanced Surgical
Signature: /s/ Thomas Fistek for Matthew Schabacker by Power of Attorney
Issuer symbol: CNMD
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2026, 16:04:11 UTC
Previous filing: 01 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schabacker Matthew	VP GM Advanced Surgical	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO	/s/ Thomas Fistek for Matthew Schabacker by Power of Attorney	04 Mar 2026	0002066553

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNMD	RSUs (Restricted Stock Units)	Award		+9,827		$0.000000^*	9,827	02 Mar 2026	Common Stock	9,827	$0.000000	Direct	F1
transaction	CNMD	Options To Purchase Common Stock	Award		+11,646		$0.000000^*	11,646	02 Mar 2026	Common Stock	11,646	$45.79	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.
F2	The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

Content

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.